Oppenheimer analyst Leland Gershell lowered the price target on Recro Pharma (NASDAQ: REPH) to $18.00 (from $20.00) after the company ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE